Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials.

ABSTRACT:

Objective

To identify drug classes and individual selective serotonin reuptake inhibitors (SSRIs) with high rates of remission and low risk of adverse events in the treatment of panic disorder with or without agoraphobia.

Design

Systematic review and network meta-analysis.

Data sources

Embase, Medline, and ClinicalTrials.gov from inception to 17 June 2021.

Eligibility criteria for study selection

Randomised controlled trials that included adults aged ≥18 years with a diagnosis of panic disorder, compared drugs used to treat the panic disorder, and measured the outcomes of interest, including remissions, dropouts, and adverse events.

Methods

Risk of bias in the included studies was assessed using the revised Cochrane risk of bias tool for randomised trial

SUBMITTER: Chawla N 

PROVIDER: S-EPMC8767458 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature